Coriolus versicolor Polysaccharide Peptide Slows Progression of Advanced Non-Small Cell Lung Cancer

Authors: K.W.Y. Tsang, C.L. Lam, C. Yan, J.C. Mak, G.C. Ooi, J.C. Ho, B. Lam, R. Man, J.S. Sham, and W.K. Lam

Journal: Respiratory Medicine

Study Design: Double-blind, placebo-controlled, randomized study

Participants: 68 patients with advanced non-small cell lung cancer (NSCLC) who had completed conventional treatment

Trial Length: 28 days

Intervention:

• PSP group (n = 34): 3 capsules of purified Yun-zhi polysaccharide peptide (PSP) three times daily
• Control group (n = 34): 3 identical placebo capsules three times daily

Primary Outcomes: NSCLC-specific morbidity

Secondary Outcomes: Safety profile of PSPSummary: The study investigated the effects of a 28-day administration of PSP on patients with advanced NSCLC who had completed conventional treatment. The results showed that PSP treatment was associated with a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percentage of body fat. Although there was no improvement in NSCLC-related symptoms, significantly fewer patients in the PSP group withdrew from the study due to disease progression compared to the control group. No adverse reactions were reported. The study concludes that PSP treatment may slow the deterioration in patients with advanced NSCLC.